Skip to main content

Table 7 Responsiveness: Change in ADCS-ADL-MCI scores by change in other trial measures (baseline to month 36)

From: Psychometric properties of the Alzheimer’s Disease Cooperative Study – Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial

ADCS-ADL-MCI Total Score

N

Mean Change (SD)a

Mean Change (95% Confidence Interval)a

Median Change (IQR)

Effect Sizeb

ANOVA/t-testc

(p-value)

ANOVA p for linear trend

Change in GDS

 Improvement

56

-1.71 (5.79)

-1.71 (-3.23, -0.20)

-1 (-3, 1)

-0.51

 < 0.001

 < 0.001

 No change

218

-0.54 (5.28)

-0.54 (-1.24, 0.16)

0 (-3, 2)

-0.13

 Worsening

200

-12.36 (10.61)

-12.36 (-13.83, -10.89)

-11 (-18, -5)

-2.75

Change in CDR-SB

 Improvement

129

0.40 (3.73)

0.40 (-0.24, 1.05)

0 (-1, 2)

0.10

 < 0.001

 < 0.001

 No change

69

-0.77 (4.77)

-0.77 (-1.89, 0.36)

-1 (-3, 2)

-0.21

 Worsening

272

-9.69 (10.66)

-9.69 (-10.96, -8.43)

-8 (-15, -2)

-2.16

Change in Global CDR Score

 Improvement

21

0.57 (3.14)

0.57 (-0.77, 1.91)

1 (-1, 3)

0.13

 < 0.001

 < 0.001

 No change

307

-1.50 (5.40)

-1.50 (-2.11, -0.90)

-1 (-4, 2)

-0.39

 Worsening

142

-15.41 (10.73)

-15.41 (-17.17, -13.64)

-13 (-22, -8)

-3.21

Change in CDR Functional Domain Score

 Improvement

89

-0.12 (5.23)

-0.12 (-1.21, 0.96)

1 (-2, 3)

-0.03

 < 0.001

 < 0.001

 No change

151

-0.75 (4.53)

-0.75 (-1.48, -0.03)

0 (-3, 2)

-0.20

 Worsening

231

-10.97 (10.81)

-10.97 (-12.37, -9.58)

-9 (-17, -2)

-2.50

  1. SD Standard Deviation, ANOVA Analysis of Variance, IQR Interquartile Range
  2. a Mean change between baseline and month 36
  3. b Effect size = mean change/Baseline SD
  4. c Parametric P-value for between-group comparisons: ANOVA/t-test for continuous variables